Primary navigation

    Astagraf XL

    Drug - Astagraf XL (tacrolimus) [Astellas Pharmaceuticals]

    March 2014

    Therapeutic area - Immunosuppresant

    Approval criteria

    • Patient has received a kidney transplant AND
    • Patient has documented non-compliance with generic tacrolimus

    Quantity limit

    34 per 34 days

    Background

    ASTAGRAF XL (tacrolimus extended-release capsules) is approved for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction.

    Questions?

    MHCP Provider Call Center 651-431-2700 or 800-366-5411

    back to top